Compliance as condition for therapeutical success. Considerations on compliance, adherence and persistence based on hypolipemic therapy Review article
Article Sidebar
Published:
Mar 31, 2009
Keywords:
compliance, adherence, persistence, statins, cardiovascular diseases, prevention
Main Article Content
Abstract
There is a number of clinical trials showing evidence for significant benefits from using statins in primary and secondary prevention of cardio-vascular diseases. Effect of these medicines may be only seen in patients compliant with prescribed therapy – taking proper doses on regular basis. Factors influencing good-, partialand non-adherence and persistence are discussed, as well different approaches to studying these phenomena. Patient-physician cooperation in statin therapy is relatively better comparing to other cardiovascular treatments. It is significantly influenced by good tolerance to statins, and long asymptomatic period in hyperlipidemia on the other hand. Compliance should be improved by multilayer activities in socio-economic politics, public health and directed education of health providers and patients.
Downloads
Download data is not yet available.
Article Details
How to Cite
Ciołkowska , M., & Mamcarz , A. (2009). Compliance as condition for therapeutical success. Considerations on compliance, adherence and persistence based on hypolipemic therapy. Cardiology in Practice, 3(1), 27-31. Retrieved from https://journalsmededu.pl/index.php/kwp/article/view/1668
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Stossel T.P.: The discovery of statins. Cell 2008, 134(6): 903-905.
2. Pedersen T.R., Kjekshus J., Berg K., Haghfelt T., Færgeman O., Thorgeirsson G., Pyörälä K., Miettinen T., Wilhelmsen L., Olsson A.G., Wedel H.: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344(8934): 1383-89.
3. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 1998; 339(19): 1349-1357.
4. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M.O., Wun C.-C., Davis B.R., Braunwald E.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 1996, 335(14): 1001-1009.
5. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., Macfarlane P.W., McKillop J.H., Packard C.J.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 1995, 333(20): 1301-1307.
6. Collins R., Armitage J., Parish S., Sleight P., Peto R.: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360(9326): 7-22.
7. Gislason G.H., Rasmussen J.N., Abildstrom S.Z., Schramm T.K., Hansen M.L., Buch P., Sørensen R., Folke F., Gadsbøll N., Rasmussen S., Køber L., Madsen M., Torp-Pedersen C.: Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes. Circulation 2007, 116(7): 737-744.
8. Ho P.M., Magid D.J., Shetterly S.M., Olson K.L., Maddox T.M., Peterson P.N., Masoudi F.A., Rumsfeld J.S.: Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am. Heart. J. 2008, 155(4): 772-779.
9. International Society of Pharmacoeconomics and Outcome Research – ISPOR, Medication Compliance and Persistence Special Interest Group (MCP).
10. Cramer J.A., Roy A., Burrell A., Fairchild C.J., Fuldeore M.J., Ollendorf D.A., Wong P.K.: Medication compliance and persistence: terminology and definitions. Value Health 2008, 11(1): 44-47.
11. Insull W.: The problem of compliance to cholesterol altering therapy. J. Intern. Med. 1997, 241: 317-325.
12. Adherence to long-term therapies: evidence for action. WHO 2003.
13. Avorn J., Monette J., Lacour A., Bohn R.L., Monane M., Mogun H., LeLorier J.: Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998, 279(18): 1458-1462.
14. Kulkarni S.P., Alexander K.P., Lytle B., Heiss G., Peterson E.D., Hill D., Hill C.: Long-term adherence with cardiovascular drug regimens. Am. Heart. J. 2006, 151(1): 185-191.
15. Gislason G.H., Rasmussen J.N., Abildstrøm S.Z., Gadsbøll N., Buch P., Friberg J., Rasmussen S., Køber L., Stender S., Madsen M., Torp-Pedersen C.: Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur. Heart. J. 2006, 27(10): 1153-1158.
16. Simpson E., Beck C., Richard H., Eisenberg M.J., Pilote L.: Drug prescriptions after acute myocardial infarction: dosage, compliance and persistance. Am. Heart. J. 2003, 145(3): 438-444.
17. Benner J.S., Glynn R.J., Mogun H.: Long-term persistence in use of statin therapy in elderly patients. JAMA 2002, 288(4): 455-461.
18. Jackevicius C.A., Mamdani M., Tu J.V.: Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002, 288(4): 462-467.
19. Perreault S., Blais L., Dragomir A., Bouchard M.H., Lalonde L., Laurier C., Collin J.: Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur. J. Clin. Pharmacol. 2005, 61(9): 667-674.
20. Chapman R.H., Benner J.S., Petrilla A.A., Tierce J.C., Collins S.R., Battleman D.S., Schwartz J.S.: Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch. Intern. Med. 2005, 165(23): 1147-1152.
21. Lachaine J., Rinfret S., Merikle E.P., Tarride J.E.: Persistence and adherence to cholesterol lowering agents: evidence from Régie de l’Assurance Maladie du Québec data. Am. Heart. J. 2006, 152(1): 164-169.
22. Foody J.M., Joyce A.T., Rudolph A.E., Liu L.Z., Benner J.S.: Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study. Curr. Med. Res. Opin. 2008, 24(7): 1987-2000.
23. Andrade S.E., Walker A.M., Gottlieb L.K., Hollenberg N.K., Testa M.A., Saperia G.M., Platt R.: Discontinuation of antihyperlipidemic drugs – do rates reported in clinical trials reflect rates in primary care settings? N. Engl. J. Med. 1995, 332(17): 1125-3.
24. Thiebaud P., Patel B.V., Nichol M.B., Berenbeim D.M.: The effect of switching on compliance and persistance: the case of statin treatment. Am. J. Manag. Care 2005; 11(11): 670-674.
25. Haynes R.B., McDonald H.P., Garg A.X.: Helping patients follow prescribed treatment: clinical applications. JAMA 2002, 288(22): 2880-2883.
2. Pedersen T.R., Kjekshus J., Berg K., Haghfelt T., Færgeman O., Thorgeirsson G., Pyörälä K., Miettinen T., Wilhelmsen L., Olsson A.G., Wedel H.: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344(8934): 1383-89.
3. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 1998; 339(19): 1349-1357.
4. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M.O., Wun C.-C., Davis B.R., Braunwald E.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 1996, 335(14): 1001-1009.
5. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., Macfarlane P.W., McKillop J.H., Packard C.J.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 1995, 333(20): 1301-1307.
6. Collins R., Armitage J., Parish S., Sleight P., Peto R.: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360(9326): 7-22.
7. Gislason G.H., Rasmussen J.N., Abildstrom S.Z., Schramm T.K., Hansen M.L., Buch P., Sørensen R., Folke F., Gadsbøll N., Rasmussen S., Køber L., Madsen M., Torp-Pedersen C.: Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes. Circulation 2007, 116(7): 737-744.
8. Ho P.M., Magid D.J., Shetterly S.M., Olson K.L., Maddox T.M., Peterson P.N., Masoudi F.A., Rumsfeld J.S.: Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am. Heart. J. 2008, 155(4): 772-779.
9. International Society of Pharmacoeconomics and Outcome Research – ISPOR, Medication Compliance and Persistence Special Interest Group (MCP).
10. Cramer J.A., Roy A., Burrell A., Fairchild C.J., Fuldeore M.J., Ollendorf D.A., Wong P.K.: Medication compliance and persistence: terminology and definitions. Value Health 2008, 11(1): 44-47.
11. Insull W.: The problem of compliance to cholesterol altering therapy. J. Intern. Med. 1997, 241: 317-325.
12. Adherence to long-term therapies: evidence for action. WHO 2003.
13. Avorn J., Monette J., Lacour A., Bohn R.L., Monane M., Mogun H., LeLorier J.: Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998, 279(18): 1458-1462.
14. Kulkarni S.P., Alexander K.P., Lytle B., Heiss G., Peterson E.D., Hill D., Hill C.: Long-term adherence with cardiovascular drug regimens. Am. Heart. J. 2006, 151(1): 185-191.
15. Gislason G.H., Rasmussen J.N., Abildstrøm S.Z., Gadsbøll N., Buch P., Friberg J., Rasmussen S., Køber L., Stender S., Madsen M., Torp-Pedersen C.: Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur. Heart. J. 2006, 27(10): 1153-1158.
16. Simpson E., Beck C., Richard H., Eisenberg M.J., Pilote L.: Drug prescriptions after acute myocardial infarction: dosage, compliance and persistance. Am. Heart. J. 2003, 145(3): 438-444.
17. Benner J.S., Glynn R.J., Mogun H.: Long-term persistence in use of statin therapy in elderly patients. JAMA 2002, 288(4): 455-461.
18. Jackevicius C.A., Mamdani M., Tu J.V.: Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002, 288(4): 462-467.
19. Perreault S., Blais L., Dragomir A., Bouchard M.H., Lalonde L., Laurier C., Collin J.: Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur. J. Clin. Pharmacol. 2005, 61(9): 667-674.
20. Chapman R.H., Benner J.S., Petrilla A.A., Tierce J.C., Collins S.R., Battleman D.S., Schwartz J.S.: Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch. Intern. Med. 2005, 165(23): 1147-1152.
21. Lachaine J., Rinfret S., Merikle E.P., Tarride J.E.: Persistence and adherence to cholesterol lowering agents: evidence from Régie de l’Assurance Maladie du Québec data. Am. Heart. J. 2006, 152(1): 164-169.
22. Foody J.M., Joyce A.T., Rudolph A.E., Liu L.Z., Benner J.S.: Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study. Curr. Med. Res. Opin. 2008, 24(7): 1987-2000.
23. Andrade S.E., Walker A.M., Gottlieb L.K., Hollenberg N.K., Testa M.A., Saperia G.M., Platt R.: Discontinuation of antihyperlipidemic drugs – do rates reported in clinical trials reflect rates in primary care settings? N. Engl. J. Med. 1995, 332(17): 1125-3.
24. Thiebaud P., Patel B.V., Nichol M.B., Berenbeim D.M.: The effect of switching on compliance and persistance: the case of statin treatment. Am. J. Manag. Care 2005; 11(11): 670-674.
25. Haynes R.B., McDonald H.P., Garg A.X.: Helping patients follow prescribed treatment: clinical applications. JAMA 2002, 288(22): 2880-2883.